Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
The neonatal Fc receptor (FcRn) preserves IgG by preventing lysosomal degradation, thereby extending IgG half-life. Inhibition of FcRn enhances the clearance of pathogenic IgG autoantibodies, resulting in rapid and reversible reductions in circulating AChR and MuSK antibodies without causing broad immunosuppression. This educational program for neurologists delivers a focused, clinically relevant update on FcRn blockade in the management of generalized myasthenia gravis (gMG), highlighting the pathophysiologic rationale for targeting FcRn and its translation into meaningful patient benefit.
Target Audience
This educational activity is directed toward neurologists, neurology nurses, specialty nurse practitioners and physician assistants, and other health care practitioners involved in managing generalized myasthenia gravis.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Outline the role of FcRN in the pathophysiology of generalized myasthenia gravis
- Evaluate emerging data for FcRN-targeted therapies for generalized myasthenia gravis in relation to treatment outcomes
- Integrate novel agents into individualized multidisciplinary management plans for patients with generalized myasthenia gravis
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here